Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

632 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines-an exploratory sub-study of the BRACE trial.
Messina NL, Germano S, McElroy R, Bonnici R, Grubor-Bauk B, Lynn DJ, McDonald E, Nicholson S, Perrett KP, Pittet LF, Rudraraju R, Stevens NE, Subbarao K, Curtis N; BRACE trial. Messina NL, et al. Among authors: subbarao k. EBioMedicine. 2024 May;103:105100. doi: 10.1016/j.ebiom.2024.105100. Epub 2024 Apr 24. EBioMedicine. 2024. PMID: 38663355 Free PMC article.
Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO).
McLeod C, Ramsay J, Flanagan KL, Plebanski M, Marshall H, Dymock M, Marsh J, Estcourt MJ, Wadia U, Williams PCM, Tjiam MC, Blyth C, Subbarao K, Nicholson S, Faust S, Thornton RB, Mckenzie A, Snelling TL, Richmond P. McLeod C, et al. Among authors: subbarao k. Trials. 2023 Mar 18;24(1):202. doi: 10.1186/s13063-023-07225-z. Trials. 2023. PMID: 36934272 Free PMC article.
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster.
Nolan TM, Deliyannis G, Griffith M, Braat S, Allen LF, Audsley J, Chung AW, Ciula M, Gherardin NA, Giles ML, Gordon TP, Grimley SL, Horng L, Jackson DC, Juno JA, Kedzierska K, Kent SJ, Lewin SR, Littlejohn M, McQuilten HA, Mordant FL, Nguyen THO, Soo VP, Price B, Purcell DFJ, Ramanathan P, Redmond SJ, Rockman S, Ruan Z, Sasadeusz J, Simpson JA, Subbarao K, Fabb SA, Payne TJ, Takanashi A, Tan CW, Torresi J, Wang JJ, Wang LF, Al-Wassiti H, Wong CY, Zaloumis S, Pouton CW, Godfrey DI. Nolan TM, et al. Among authors: subbarao k. EBioMedicine. 2023 Dec;98:104878. doi: 10.1016/j.ebiom.2023.104878. Epub 2023 Nov 27. EBioMedicine. 2023. PMID: 38016322 Free PMC article. Clinical Trial.
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ, Mordant FL, Amarilla AA, Modhiran N, Liang B, Li Z, Wijesundara DK, Lackenby JA, Griffin P, Bennet JK, Hensen L, Zhang W, Nguyen THO, Tran MH, Tapley P, Barnes J, Reading PC, Kedzierska K, Ranasinghe C, Subbarao K, Watterson D, Young PR, Munro TP. Chappell KJ, et al. Among authors: subbarao k. EBioMedicine. 2023 Nov;97:104842. doi: 10.1016/j.ebiom.2023.104842. Epub 2023 Oct 20. EBioMedicine. 2023. PMID: 37865043 Free PMC article. Clinical Trial.
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
Deliyannis G, Gherardin NA, Wong CY, Grimley SL, Cooney JP, Redmond SJ, Ellenberg P, Davidson KC, Mordant FL, Smith T, Gillard M, Lopez E, McAuley J, Tan CW, Wang JJ, Zeng W, Littlejohn M, Zhou R, Fuk-Woo Chan J, Chen ZW, Hartwig AE, Bowen R, Mackenzie JM, Vincan E, Torresi J, Kedzierska K, Pouton CW, Gordon TP, Wang LF, Kent SJ, Wheatley AK, Lewin SR, Subbarao K, Chung AW, Pellegrini M, Munro T, Nolan T, Rockman S, Jackson DC, Purcell DFJ, Godfrey DI. Deliyannis G, et al. Among authors: subbarao k. EBioMedicine. 2023 Jun;92:104574. doi: 10.1016/j.ebiom.2023.104574. Epub 2023 May 4. EBioMedicine. 2023. PMID: 37148585 Free PMC article.
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months.
Mordant FL, Price OH, Rudraraju R, Slavin MA, Marshall C, Worth LJ, Peck H, Barr IG, Sullivan SG, Subbarao K. Mordant FL, et al. Among authors: subbarao k. Influenza Other Respir Viruses. 2023 Jan;17(1):e13072. doi: 10.1111/irv.13072. Epub 2022 Nov 30. Influenza Other Respir Viruses. 2023. PMID: 36451293 Free PMC article.
Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells.
Nguyen THO, Rowntree LC, Allen LF, Chua BY, Kedzierski L, Lim C, Lasica M, Tennakoon GS, Saunders NR, Crane M, Chee L, Seymour JF, Anderson MA, Whitechurch A, Clemens EB, Zhang W, Chang SY, Habel JR, Jia X, McQuilten HA, Minervina AA, Pogorelyy MV, Chaurasia P, Petersen J, Menon T, Hensen L, Neil JA, Mordant FL, Tan HX, Cabug AF, Wheatley AK, Kent SJ, Subbarao K, Karapanagiotidis T, Huang H, Vo LK, Cain NL, Nicholson S, Krammer F, Gibney G, James F, Trevillyan JM, Trubiano JA, Mitchell J, Christensen B, Bond KA, Williamson DA, Rossjohn J, Crawford JC, Thomas PG, Thursky KA, Slavin MA, Tam CS, Teh BW, Kedzierska K. Nguyen THO, et al. Among authors: subbarao k. Cell Rep Med. 2023 Apr 18;4(4):101017. doi: 10.1016/j.xcrm.2023.101017. Epub 2023 Mar 27. Cell Rep Med. 2023. PMID: 37030296 Free PMC article.
Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities.
Zhang W, Kedzierski L, Chua BY, Mayo M, Lonzi C, Rigas V, Middleton BF, McQuilten HA, Rowntree LC, Allen LF, Purcell RA, Tan HX, Petersen J, Chaurasia P, Mordant F, Pogorelyy MV, Minervina AA, Crawford JC, Perkins GB, Zhang E, Gras S, Clemens EB, Juno JA, Audsley J, Khoury DS, Holmes NE, Thevarajan I, Subbarao K, Krammer F, Cheng AC, Davenport MP, Grubor-Bauk B, Coates PT, Christensen B, Thomas PG, Wheatley AK, Kent SJ, Rossjohn J, Chung AW, Boffa J, Miller A, Lynar S, Nelson J, Nguyen THO, Davies J, Kedzierska K. Zhang W, et al. Among authors: subbarao k. Nat Immunol. 2023 Jun;24(6):966-978. doi: 10.1038/s41590-023-01508-y. Epub 2023 May 29. Nat Immunol. 2023. PMID: 37248417 Free PMC article.
Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
Liu Y, Sánchez-Ovando S, Carolan L, Dowson L, Khvorov A, Jessica Hadiprodjo A, Tseng YY, Delahunty C, Khatami A, Macnish M, Dougherty S, Hagenauer M, Riley KE, Jadhav A, Harvey J, Kaiser M, Mathew S, Hodgson D, Leung V, Subbarao K, Cheng AC, Macartney K, Koirala A, Marshall H, Clark J, Blyth CC, Wark P, Kucharski AJ, Sullivan SG, Fox A. Liu Y, et al. Among authors: subbarao k. Vaccine. 2023 Nov 22;41(48):7192-7200. doi: 10.1016/j.vaccine.2023.10.034. Epub 2023 Oct 28. Vaccine. 2023. PMID: 37903679 Free article.
632 results